Combined microPET/CT for imaging of hepatocellular carcinoma in mice

Frontiers in Bioscience

Volumn 14, Issue 6, 2009, Pages 2193-2202

  Von Falck, Christian ^a,b   Rodt, Thomas ^a,b   Halter, Roman ^b   Spanel, Reinhard ^c   Galanski, Michael ^a   Borlak, Juergen ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c Institute of Pathology   (Germany)

Author keywords

Hepatocellular carcinoma; MicroCT; MicroPET; Mouse

Indexed keywords

MURINAE; MUS; MUS MUSCULUS;

ANIMAL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; METHODOLOGY; MOUSE; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TRANSGENIC MOUSE;

ANIMALS; GENE EXPRESSION PROFILING; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 63849161097     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3371     Document Type: Article

References (29)

1. Schafer DF, Sorrell MF: Hepatocellular carcinoma. Lancet 353, 1253-1257 (1999). (Pubitemid 29168472)
2. Avila MA, Bersain C, Sangro B, Priteo J: New therapies for hepatocellular carcinoma. Oncogene 25, 3866-3884 (2006). (Pubitemid 43980482)
3. Tonjes RR, Lohler J, O'Sullivan JF, Kay GF, Schmidt GH, Dalemans W, Pavirani A, Paul D. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene 104, 765-768 (1995).
4. Wang Y, Ripperger J, Fey GH, Samols D, Kordula T, Wetzler M, Van Etten RA, Baumann H. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology 30, 682-692 (1999).
5. Ostrowski J, Woszczynski M, Kowalczyk P, Wocial T, Henning E, Trzeciak L, Janik P, Bomsztyk K. Increased activity of MAP, p70S6 and p90rs kinases is associated with AP-1 activation in spontaneous liver tumours, but not in adjacent tissue in mice. Br J Cancer 82, 1041-1050 (2000). (Pubitemid 30128857)
6. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24, 1809-1819 (2005). (Pubitemid 40462784)
7. Weber SM, Peterson KA, Durkee B, Qi C, Longino M, Warner T, Lee FT Jr, Weichert JP. Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy in dependent on adequate contrast enhancement. J Surg Res 119, 41-45 (2004). (Pubitemid 38581983)
8. Kessler RM, Ellis JR, Eden M. Analysis of Emission Tomographic Scan Data: Limitations Imposed by Resolution and Background. J Comput Assist Tomogr 8, 514-522 (1984). (Pubitemid 14122897)
9. Wang Y, Seidel J, Tsui BM, Vaquerro JJ, Pomper MG. Performance evaluation of the GE Healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med 47, 1891-1900 (2006). (Pubitemid 47545013)
10. (no authors listed). Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 22, 983-993 (1995).
11. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66, 3355-3358 (2006).
12. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5, 741-754 (2006). (Pubitemid 44323701)
13. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2, 62-70 (2000). (Pubitemid 30123181)
14. Chang CH, Jan ML, Fan KH, Wang HE, Tsai TH, Chen CF, Fu YK, Lee TW. Longitudinal evaluation of tumor metastasis by an FDG-microPET/microCT dual-imaging modality in a lung carcinoma-bearing mouse model. Anticancer Res. 26, 159-166 (2006).
15. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM. Murine lung tumor measurement using respiratory-gated microcomputed tomography. Invest Radiol. 40, 263-269 (2005). (Pubitemid 40571681)
16. Ford NL, Graham KC, Groom AC, Macdonald IC, Chambers AF, Holdsworth DW. Time-Course Characterization of the Computed Tomography Contrast Enhancement of an Iodinated Blood-Pool Contrast Agent in Mice Using a Volumetric Flat-Panel Equipped Computed Tomography Scanner. Invest Radiol. 41, 384-390 (2006). (Pubitemid 44284200)
17. Montet X, Pastor CM, Vallée JP, Becker CD, Geissbuhler A, Morel DR, Meda P. Improved visualization of vessels and hepatic tumors by micro-computed tomography (CT) using iodinated liposomes. Invest Radiol 42, 2236-2241 (2007).
18. Ohta S, Lai EW, Morris JC, Bakan DA, Klaunberg B, Cleary S, Powers JF, Tischler AS, Abu-Asab M, Schimel D, Pacak K. MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. Int J Cancer 119, 2236-2241 (2006). (Pubitemid 44423688)
19. Weichert JP, Longino MA, Bakan DA, Spigarelli MG, Schwendner SW, Francis IR, Counsell RE. Targeted polyiodinated triglycerides for hepatic computed tomography. Invest Radiol 29, Suppl 2: S284-285 (1994). (Pubitemid 24221138)
20. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 234, 468-478 (2005). (Pubitemid 40139918)
21. Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, Shimazaki Y. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4, 1-9 (2005).
22. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP. Positron-emission tomography with (18F)fluordeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126, 549-559 (2000).
23. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94, 3314-3319 (1999).
24. Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH. Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepato-Gastroenterology 50, 2154-2156 (2003).
25. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36, 1811-1817 (1995).
26. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN, Han KH, Lee WJ, Yoo N, Lim SM, Park JH. Analysis of gene expression profiles of hepatocellular carcinomas with regard to F-18-FDG uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31, 1621-1630 (2004). (Pubitemid 40104608)
27. Yang SH, Suh KS, Lee HW. The role of (18F)-FDGPET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 12, 1655-1660 (2006). (Pubitemid 44742545)
28. Tascherau R, Chow PL, Chatziioannou AE. Monte carlo simulations of dose from microCT imaging procedures in a realistic mouse phantom. Med Phys 33, 216-224 (2006). (Pubitemid 43121051)
29. Funk T, Sun M, Hasegawa BH. Radiation dose estimate in small animal SPECT and PET. Med Phys 31, 2680-2686 (2004). (Pubitemid 39287885)